vigabatrin
vigabatrin is listed in the FDA National Drug Code directory with 15 NDC codes, marketed under brand names including vigabatrin for oral solution, vigabatrin, VIGAFYDE. Available dosage forms: powder, for solution, tablet, film coated, solution, for solution.
Drug details
- Generic Name
- vigabatrin
- Brand Names
- vigabatrin for oral solution, vigabatrin, VIGAFYDE, VIGABATRIN, SABRIL, VIGADRONE, Vigabatrin
- Application Number
- ANDA213519
- Sponsor
- Camber Pharmaceuticals, Inc.
- NDC Codes
- 15
- Dosage Forms
- POWDER, FOR SOLUTION, TABLET, FILM COATED, SOLUTION, FOR SOLUTION
- Routes
- ORAL
- Active Ingredients
- VIGABATRIN
Indications and Usage
1 INDICATIONS AND USAGE Vigabatrin tablets are indicated for the treatment of: • Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; Vigabatrin tablets are not indicated as a first line agent ( 1.1 ) • Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions ( 5.1 ) ]. Vigabatrin tablets are not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) Vigabatrin tablets are indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [ see Warnings and Precautions ( 5.1 ) ]